Neuroendocrine Tumours
Research activity includes gastroenteropancreatic neuroendocrine tumours, with attention to diffuse and locally unresectable disease and cases with well-differentiated and intermediate-differentiated histology.
- Gastrointestinal neuroendocrine neoplasms
- Histopathologically confirmed tumour classification
- Locally unresectable disease
The sponsor’s interest in this area is closely linked to radionuclide-based care pathways for complex neuroendocrine malignancies.
Radionuclide Therapy
Clinical work focuses on peptide receptor radionuclide therapy using lutetium-177 and yttrium-90 labelled agents, with emphasis on therapeutic selection for neuroendocrine tumours.
- 177Lu-DOTATATE
- 90Y-DOTATATE
- Theranostic isotope mixtures
This area reflects a strong therapeutic interest in targeted radiopharmaceutical treatment for solid tumours with somatostatin receptor expression.
Personalized Dosimetry
Research includes personalized dosimetry and treatment planning strategies aimed at optimizing radionuclide delivery in GEPNET care.
- Individualized treatment algorithms
- Radiation dose estimation
- Patient-specific therapy planning
The sponsor is engaged in precision-oriented nuclear medicine approaches that support tailored treatment decisions in complex tumour settings.
Prostate Cancer Imaging
Another area of interest is prostate cancer, particularly the use of PSMA-targeted radiotracers for diagnosis and metastatic disease assessment.
- PSMA-based molecular imaging
- Metastasis evaluation
- Treatment planning in prostate malignancy
This work aligns with nuclear medicine applications that support lesion detection and clinical decision-making in advanced prostate cancer.
